EP Patent

EP4004138A1 — Dihydroergotamine mesylate formulations and pre-filled injectors for therapeutic delivery of the same

Assigned to Scienture Inc · Expires 2022-06-01 · 4y expired

What this patent protects

The present disclosure is directed to formulations and methods for treating or preventing head pain, including migraines, with dihydroergotamine mesylate.

USPTO Abstract

The present disclosure is directed to formulations and methods for treating or preventing head pain, including migraines, with dihydroergotamine mesylate.

Drugs covered by this patent

Patent Metadata

Patent number
EP4004138A1
Jurisdiction
EP
Classification
—
Expires
2022-06-01
Drug substance claim
No
Drug product claim
No
Assignee
Scienture Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.